Pyrovalerone

Pyrovalerone is a psychoactive drug with stimulant effects. It was developed in the late 1960s and has since been used for therapeutic purposes, although its use has been restricted due to potential for abuse and addiction.

History[edit | edit source]

Pyrovalerone was first synthesized in the late 1960s by the pharmaceutical company Abbott Laboratories. It was initially developed as a treatment for chronic fatigue and lethargy, but its use has since been limited due to its potential for abuse and addiction.

Pharmacology[edit | edit source]

Pyrovalerone acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing the levels of these neurotransmitters in the brain. This results in increased alertness, focus, and physical energy. However, it also has the potential to cause a range of side effects, including insomnia, anxiety, and in severe cases, psychosis.

Legal status[edit | edit source]

Due to its potential for abuse, Pyrovalerone is a controlled substance in many countries. In the United States, it is classified as a Schedule V drug under the Controlled Substances Act, indicating that it has a low potential for abuse relative to drugs in higher schedules.